BioCryst Pharmaceuticals
BCRX
197 hedge funds and large institutions have $1.48B invested in BioCryst Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 66 increasing their positions, 67 reducing their positions, and 28 closing their positions.
71% more call options, than puts
Call options by funds: $90.6M | Put options by funds: $53.1M
14% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 28
1% more funds holding
Funds holding: 195 → 197 (+2)
1% less repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 67
1.13% less ownership
Funds ownership: 58.87% → 57.74% (-1.1%)
10% less capital invested
Capital invested by funds: $1.65B → $1.48B (-$168M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| 1 |
Two Sigma Advisers
New York
|
+$19.1M |
| 2 |
Fisher Asset Management
Camas,
Washington
|
+$15.7M |
| 3 |
State Street
Boston,
Massachusetts
|
+$13.4M |
| 4 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$11.1M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$9.86M |
Top Sellers
| 1 |
DM
Deerfield Management
New York
|
-$41M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$11.2M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$10.8M |
| 4 |
Renaissance Technologies
New York
|
-$9.85M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$8.58M |
BCRX Hedge Fund Activity: Q3 2021 in Review
197 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q3 2021, worth a combined $1.48B — down 10% from $1.65B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new BCRX positions and 28 closed out — a net gain of 4 holders — while 66 added to existing stakes and 67 trimmed.
The largest buyer was Two Sigma Advisers, adding an estimated $19.1M. The largest seller was Deerfield Management, cutting an estimated $41M.
- 197 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q3 2021, up from 195 in Q2 2021.
- Funds reported $1.48B of BioCryst Pharmaceuticals stock for Q3 2021, down 10% quarter-over-quarter.
- 32 funds opened new BioCryst Pharmaceuticals positions in Q3 2021 and 28 closed out, a net change of +4 holders.
- The largest BioCryst Pharmaceuticals buyer in Q3 2021 was Two Sigma Advisers, an estimated $19.1M added.
- The largest BioCryst Pharmaceuticals seller in Q3 2021 was Deerfield Management, an estimated $41M sold.
Based on aggregated 13F filings for Q3 2021.